{"nctId":"NCT02326298","briefTitle":"An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","startDateStruct":{"date":"2014-12-16","type":"ACTUAL"},"conditions":["Psoriasis","Plaque Psoriasis"],"count":234,"armGroups":[{"label":"CZP 200 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab Pegol"]},{"label":"CZP 400 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab Pegol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870","CZP"]},{"name":"Placebo","otherNames":["PBO"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provided informed consent\n* Adult men or women \\>= 18 years\n* Chronic plaque psoriasis for at least 6 months\n* Baseline psoriasis activity and severity index \\>= 12 and body surface area \\>= 10 % and Physician's Global Assessments score \\>= 3\n* Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy\n* Other protocol-defined inclusion criteria may apply\n\nExclusion Criteria:\n\n* Erythrodermic, guttate, generalized pustular form of psoriasis\n* History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol\n* Congestive heart failure\n* History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease\n* Concurrent malignancy or a history of malignancy as described in the protocol\n* History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis)\n* Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 5 months following last dose of study drug (in Czech Republic and Germany) and within 3 months for all other countries. Male subjects who are planning a partner pregnancy during the study or within 10 weeks following the last dose of study drug\n* Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study\n* Other protocol-defined exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16","description":"The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"66.5","spread":null},{"groupId":"OG002","value":"75.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16","description":"The Investigator assessed the overall severity of Psoriasis (PSO) using the following 5-point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"47.0","spread":null},{"groupId":"OG002","value":"57.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI90) Response at Week 16","description":"The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"43.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16","description":"The DLQI is a subject-reported questionnaire designed for use in adult participants with PSO. The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL). This instrument asks participants about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. It has been shown to be valid and reproducible in PSO patients. The DLQI score ranges from 0 to 30 with higher scores indicating lower HRQoL. A higher than of equal to (\\>=) 4-point change in the DLQI score (DLQI response) has been reported to be meaningful for the patient (within-patient minimal important difference Basra et al, 2015) a DLQI absolute score of lower than or equal to (=\\<) 1 indicates DLQI remission (i.e., no or small impact of the disease on HRQoL).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"0.80"},{"groupId":"OG001","value":"-9.3","spread":"0.58"},{"groupId":"OG002","value":"-10.2","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 48","description":"The Investigator assessed the overall severity of Psoriasis (PSO) using the following 5-point scale: 0= clear, 1= almost clear, 2= mild, 3= moderate, 4= severe.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null},{"groupId":"OG001","value":"69.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 48","description":"The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null},{"groupId":"OG001","value":"87.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":188},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Back pain","Headache","Arthralgia"]}}}